Frontiers Dynamic immune signatures of patients with advanced non–small-cell lung cancer for infection prediction after immunotherapy

Frontiers The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors

Cancers, Free Full-Text

Inflammatory and autoimmune predictive markers of response to anti‑PD‑1/PD‑L1 therapy in NSCLC and melanoma

Pharmaceutics, Free Full-Text

New predictive biomarkers for immunotherapy in NSCLC

Cancers, Free Full-Text

Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing, Genome Medicine

Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges

Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics

Frontiers Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy

Dynamics and specificities of T cells in cancer immunotherapy

Frontiers TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer